Latest market price
6.14
-0.16-2.54%
TA
Loading chart...
Snapshot
| Index | — | P/E | — | EPS (ttm) | -1.78 | Insider Own | 14.81% | Shs Outstand | 103.70M | Perf Week | -2.54% |
| Market Cap | 636.75M | Forward P/E | — | EPS next Y | -1.52 | Insider Trans | -45.15% | Shs Float | 74.64M | Perf Month | 1.66% |
| Enterprise Value | 325.75M | PEG | — | EPS next Q | -0.37 | Short Float | 14.58% | Perf Quarter | -12.78% | ||
| Income | -132.00M | P/S | — | EPS this Y | — | Short Ratio | 13.57 | Perf Half Y | -12.41% | ||
| Sales | 0.00 | P/B | 2.02 | EPS next Y | — | ROA | -37.63% | Short Interest | 10.89M | Perf YTD | 12.66% |
| Book/sh | 3.04 | P/C | 1.97 | EPS next 5Y | — | ROE | -73.18% | 52W High | 9.54 -35.64% | Perf Year | 0.00% |
| Cash/sh | 3.12 | P/FCF | — | EPS past 3/5Y | — | ROIC | -41.61% | 52W Low | 4.73 29.81% | Perf 3Y | -22.28% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | — | Gross Margin | 0.00% | Volatility | 4.22% 4.39% | Perf 5Y | — |
| Dividend TTM | — | EV/Sales | — | EPS Y/Y TTM | — | Oper. Margin | 0.00% | ATR (14) | 0.29 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 16.82 | Sales Y/Y TTM | — | Profit Margin | 0.00% | RSI (14) | 42.62 | Recom | 2.00 |
| Dividend Gr. 3/5Y | — | Current Ratio | 16.82 | EPS Q/Q | -2.13% | SMA20 | -3.09% | Beta | 0.96 | Target Price | 17.50 |
| Payout | 0.00% | Debt/Eq | 0.04 | Sales Q/Q | — | SMA50 | -8.09% | Rel Volume | 0.61 | Prev Close | 6.30 |
| Employees | 113 | LT Debt/Eq | 0.04 | Earnings | Nov 05 | SMA200 | -8.58% | Avg Volume | 875.83K | Price | 6.14 |
| IPO Date | Oct 29, 2021 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -28.00% — | Net Debt/EBITDA | — | Volume | 533,005 | Change | -2.54% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-11-26 | Reiterated | HC Wainwright & Co. | Buy | $18 |
| May-12-26 | Reiterated | Leerink Partners | $17 | |
| Mar-26-25 | Reiterated | JMP Securities | Market Outperform | $19 |
| Mar-25-25 | Reiterated | HC Wainwright & Co. | Buy | $22 |
| Mar-24-25 | Reiterated | HC Wainwright & Co. | Buy | $22 |
| Oct-18-24 | Reiterated | BTIG | Buy | $24 |
| Oct-18-24 | Reiterated | HC Wainwright & Co. | Buy | $21 → $22 |
| Oct-18-24 | Reiterated | Scotiabank | Sector Outperform | $23 |
| Jul-25-24 | Initiated | H.C | Buy | $21 |
| Nov-11-22 | Reiterated | JMP Securities | Market Outperform |
Latest News· Times ET
Oct-31-26
Sep-16-26
Sep-16-2607:31PM
Sep-07-26
Sep-07-2604:20AM
Sep-06-26
Sep-06-2611:06AM
Sep-02-26
03:52AM
Sep-01-26
Sep-01-2604:28PM
Aug-26-26
Aug-26-2604:20AM
Aug-12-26
Aug-12-2603:22PM
Jul-24-26
Jul-24-2604:04AM
Jul-08-26
Jul-08-2607:01AM
Company
Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 0 | 1 | — | — | — | — | |
| Gross Profit | 0 | 0 | 0 | -1 | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 35 | 22 | 23 | 20 | — | — | — | — | |
| Research and Development | 103 | 90 | 73 | 64 | — | — | — | — | |
| Other Operating Expense | 0 | 1 | 0 | 0 | — | — | — | — | |
| Operating Income | -138 | -113 | -96 | -85 | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | 0 | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 7 | 7 | 9 | 9 | — | — | — | — | |
| Net Income Before Taxes | -132 | -106 | -87 | -76 | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | 0 | — | — | — | — | |
| Consolidated Net Income | -132 | -106 | -87 | -76 | — | — | — | — | |
| Net Income From Continuing Operations | -132 | -106 | -87 | -76 | — | — | — | — | |
| Net Income | -132 | -106 | -87 | -76 | — | — | — | — | |
| EPS (Recurring) | -1.78 | -1.76 | -1.75 | -1.93 | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -1.78 | -1.76 | -1.75 | -1.93 | — | — | — | — | |
| EPS (Diluted) | -1.78 | -1.76 | -1.75 | -1.93 | — | — | — | — | |
| EBITDA | -132 | -105 | -86 | -75 | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | — | — | — | |
| Gross Margin | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | |
| Shares Outstanding | 95 | 60 | 50 | 40 | — | — | — | — | |
| Market Capitalization | 583 | 327 | 411 | 354 | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Gibney Anthony S | Officer | Jun 16 '26 | Sale | 6.42 | 12,824 | 82,330 | 265,354 | Jun 16 |
| Matrix Capital Management Company, LP | 10% Owner | May 07 '26 | Sale | 5.64 | 6,922,870 | 39,044,987 | 0 | May 11 |
| Kilroy Conor | Officer | Apr 16 '26 | Sale | 7.02 | 11,738 | 82,401 | 217,835 | Apr 16 |
| Kilroy Conor | Officer | Feb 17 '26 | Sale | 5.05 | 12,079 | 60,999 | 167,234 | Feb 17 |
| Plavsic Mark | Chief Technology Officer | Feb 17 '26 | Sale | 5.05 | 15,890 | 80,245 | 181,397 | Feb 17 |
| Hopkins Janet Jill | Chief Medical Officer | Feb 17 '26 | Sale | 5.06 | 20,401 | 103,229 | 232,284 | Feb 17 |
| Elazzouzi Amy | Senior Vice President, Finance | Feb 17 '26 | Sale | 5.06 | 8,549 | 43,258 | 75,532 | Feb 17 |
| de los Pinos Elisabet | Director, Officer | Feb 17 '26 | Sale | 5.06 | 47,648 | 241,099 | 409,815 | Feb 17 |
| Elazzouzi Amy | Senior Vice President, Finance | Jan 20 '26 | Sale | 4.86 | 1,581 | 7,684 | 84,081 | Jan 20 |
| de los Pinos Elisabet | Director, Officer | Jan 20 '26 | Sale | 4.86 | 16,928 | 82,270 | 457,463 | Jan 20 |
| Hopkins Janet Jill | Chief Medical Officer | Nov 17 '25 | Sale | 5.42 | 17,109 | 92,731 | 252,685 | Nov 17 |
| Elazzouzi Amy | Senior Vice President, Finance | Oct 29 '25 | Sale | 6.35 | 896 | 5,690 | 85,662 | Oct 29 |
| de los Pinos Elisabet | Director, Officer | Oct 29 '25 | Sale | 6.35 | 9,049 | 57,461 | 474,391 | Oct 29 |
| Plavsic Mark | Chief Technology Officer | Oct 16 '25 | Sale | 6.35 | 12,169 | 77,273 | 197,287 | Oct 16 |
| Elazzouzi Amy | Senior Vice President, Finance | Aug 18 '25 | Option Exercise | 3.96 | 12,899 | 51,104 | 94,280 | Aug 18 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.